Document is current

Article History

Received: 4 April 2024

Revised: 8 July 2024

Accepted: 15 July 2024

First Online: 24 July 2024

Competing interests

: Dr. Shapiro serves on the advisory boards for Parion Sciences, Ethris GmbH, and ReCode Therapeutics. He is also the Medical Director of the PCD Foundation Clinical and Research Center Network and receives salary support from the PCD Foundation. Support for research was provided to Dr. Shapiro by US NIH/ORDR/NACTS/NHLBI grant U54HL096458. The Genetic Disorders of Mucociliary Clearance Consortium (U54HL096458) is part of the National Center for Advancing Translational Sciences (NCATS) Rare Diseases Clinical Research Network (RDCRN) and supported by the RDCRN Data Management and Coordinating Center (DMCC) (U2CTR002818). RDCRN is an initiative of the Office of Rare Diseases Research (ORDR) funded through a collaboration between NCATS and National Heart, Lung, and Blood Institute (NHLBI). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institute of Health.

: This study was approved by the McGill University Health Centre-Montreal Children’s Hospital (MUHC-MCH) Research Ethics Board (Reference number 2023-9523) and was performed in accordance with the Declaration of Helsinki. Informed consent was obtained from all subjects.